Alyamany R, Alnughmush A, Alzahrani H, Alfayez M
Curr Oncol. 2024; 31(12):8094-8109.
PMID: 39727719
PMC: 11675056.
DOI: 10.3390/curroncol31120596.
Liu H, Luo H, Lee W, Chang Y, Wu Y, Wang H
Am J Cancer Res. 2024; 14(11):5389-5399.
PMID: 39659915
PMC: 11626279.
DOI: 10.62347/UJAT9290.
Chen X, Zhou H, Lv J
Cell Biochem Biophys. 2024; 82(3):1893-1906.
PMID: 38955926
DOI: 10.1007/s12013-024-01386-7.
Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U
Breast Cancer Res Treat. 2023; 203(3):497-509.
PMID: 37938495
PMC: 11052564.
DOI: 10.1007/s10549-023-07159-9.
Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T
Curr Oncol. 2023; 30(9):7836-7851.
PMID: 37754484
PMC: 10529066.
DOI: 10.3390/curroncol30090569.
Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.
Adams A, Scheckel B, Habsaoui A, Haque M, Kuhr K, Monsef I
Cochrane Database Syst Rev. 2022; 6:CD012633.
PMID: 35724934
PMC: 9208863.
DOI: 10.1002/14651858.CD012633.pub2.
Recurrent Conjunctival Squamous Cell Carcinoma and Intraocular Tumor Extension after Topical Erythropoietin: A Case Report.
Feizi S, Esfandiari H
Case Rep Ophthalmol. 2022; 13(1):89-95.
PMID: 35350235
PMC: 8921966.
DOI: 10.1159/000521735.
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).
Bennett C, Hoque S, Olivieri N, Taylor M, Aboulafia D, Lubaczewski C
EClinicalMedicine. 2021; 31:100693.
PMID: 33554084
PMC: 7846671.
DOI: 10.1016/j.eclinm.2020.100693.
Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare's reimbursement policy.
Li M, Schulz R, Chisholm-Burns M, Wang J, Lu Z
J Manag Care Spec Pharm. 2020; 26(11):1477-1486.
PMID: 33119441
PMC: 10390950.
DOI: 10.18553/jmcp.2020.26.11.1477.
Intranasal injection of recombinant human erythropoietin improves cognitive and visual impairments in chronic cerebral ischemia rats.
Zhou Y, Sun B, Guo J, Zhou G
Biomed Rep. 2020; 13(5):40.
PMID: 32934813
PMC: 7469562.
DOI: 10.3892/br.2020.1347.
Role of the erythropoietin receptor in Lung Cancer cells: erythropoietin exhibits angiogenic potential.
Liu X, Tufman A, Behr J, Kiefl R, Goldmann T, Huber R
J Cancer. 2020; 11(20):6090-6100.
PMID: 32922549
PMC: 7477424.
DOI: 10.7150/jca.36924.
Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials.
Guo L, Hu Y, Chen X, Li Q, Wei B, Ma X
Cancer Med. 2019; 8(4):1389-1400.
PMID: 30897298
PMC: 6488107.
DOI: 10.1002/cam4.1970.
Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
Bhat K, Sandler K, Duhachek-Muggy S, Alli C, Cheng F, Moatamed N
Breast Cancer Res. 2019; 21(1):17.
PMID: 30700319
PMC: 6354373.
DOI: 10.1186/s13058-019-1100-9.
Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective.
Aapro M, Gascon P, Patel K, Rodgers G, Fung S, Arantes Jr L
Front Pharmacol. 2019; 9:1498.
PMID: 30687083
PMC: 6333861.
DOI: 10.3389/fphar.2018.01498.
Erythropoietin inhibits chemotherapy-induced cell death and promotes a senescence-like state in leukemia cells.
Pham T, Ma W, Miller D, Kazakova L, Benchimol S
Cell Death Dis. 2019; 10(1):22.
PMID: 30622244
PMC: 6325163.
DOI: 10.1038/s41419-018-1274-6.
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
Noxon V, Knopf K, Norris L, Chen B, Yang Y, Qureshi Z
J Oncol Pract. 2017; 13(6):e562-e573.
PMID: 28504901
PMC: 6366245.
DOI: 10.1200/JOP.2016.019364.
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
Bian J, Chen B, Hershman D, Marks N, Norris L, Schulz R
J Clin Oncol. 2017; 35(17):1945-1951.
PMID: 28441110
PMC: 5466011.
DOI: 10.1200/JCO.2017.72.6273.
Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
Chan K, Matchett K, Coulter J, Yuen H, McCrudden C, Zhang S
Oncotarget. 2017; 8(24):38251-38263.
PMID: 28418910
PMC: 5503530.
DOI: 10.18632/oncotarget.16368.
Recombinant human erythropoietin stimulates melanoma tumor growth through activation of initiation factor eIF4E.
Julius A, Desai A, Yung R
Oncotarget. 2017; 8(18):30317-30327.
PMID: 28415825
PMC: 5444745.
DOI: 10.18632/oncotarget.16331.
Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers.
Beh C, How C, Foo J, Foong J, Selvarajah G, Rasedee A
Drug Des Devel Ther. 2017; 11:771-782.
PMID: 28352153
PMC: 5358988.
DOI: 10.2147/DDDT.S123939.
